<DOC>
	<DOCNO>NCT02142296</DOCNO>
	<brief_summary>Primary Objectives : To assess efficacy intravitreal administer Eylea prevent visual loss subject retinal pigment epithelial detachment ( PED ) subtype neovascular age-related macular degeneration ( AMD ) measure mean change BCVA Month 12 compare Baseline . Secondary Objectives : 1 . To assess safety tolerability repeat intravitreal administration Eylea subject PED subtype neovascular AMD period 1 year 2 . To assess effect repeat intravitreal administration Eylea Central Subfield Thickness ( CSFT ) , Central Subfield Volume ( CSFV ) , PED height volume . 3 . To assess effect repeat intravitreal administration Eylea vision relate quality life subject PED study type neovascular AMD assess use NEI/VFQ-25 questionnaire</brief_summary>
	<brief_title>Eylea Treat Retinal Pigment Epithelial Detachment ( RPED ) Secondary Wet Age-Related Macular Degeneration ( wAMD )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<criteria>1 . Signed , informed consent . 2 . Men woman great equal 55 year age . 3 . Recent development RPED secondary AMD . 4 . ETDRS best correct visual acuity 20/40 20/320 ( letter score 73 25 ) study eye . 5 . Willing committed able return clinic visit complete study related procedure . 1 . Any prior treatment neovascular AMD except dietary supplement vitamin . ( patient treatment na√Øve group ) 2 . Any prior concomitant therapy another investigational agent treat neovascular AMD study eye . 3 . Total lesion size great 12 disc area . 4 . Subretinal hemorrhage either 50 % total lesion area blood fovea 1 disc area size study eye . 5 . Scar fibrosis make great 50 % total lesion study eye . 6 . Scar , fibrosis atrophy involve center fovea . 7 . Presence retinal pigment epithelial tear . 8 . History vitreous hemorrhage within 4 week prior initiation study . 9 . Presence cause choroidal neovascular membrane AMD . 10 . History clinical evidence diabetic retinopathy , especially diabetic maculopathy macular edema cause , include retinal vein occlusion diabetes 11 . Prior vitrectomy surgery study eye . 12 . History retinal detachment treatment study eye . 13 . History macular hole study eye . 14 . Any intraocular/periocular surgery within 3 month initiation study . 15 . Prior trabeculectomy filter surgery study eye . 16 . Uncontrolled glaucoma , defined pressure great 25 mmHg despite treatment . 17 . Active intraocular inflammation . 18 . Active ocular/periocular infection . 19 . Any history uveitis . 20 . Active scleritis episcleritis . 21 . Aphakia pseudophakia absence posterior capsule ( unless occur result YAG posterior capsulotomy ) study eye . 22 . Previous radiation therapy region study eye . 23 . History corneal transplant corneal dystrophy study eye . 24 . Significant medial opacity include cataract may interfere visual acuity fundus photography . 25 . Any disease ocular condition , opinion investigator could either increase risk subject beyond expect standard procedure intraocular injection may consider contraindicate use investigational drug ( VEGF Trap ) . 26 . The use long acting steroid systemically intraocularly . 27 . Any history allergy Proviodine fluorescein sodium .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pigment Epithelial Detachment</keyword>
	<keyword>Age-related Macular degeneration</keyword>
</DOC>